Advanced Filters
noise

Liver Cancer Clinical Trials

A listing of Liver Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 605 clinical trials
G Gaojun Teng, M.D.

Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies

The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies.

18 years of age All Phase N/A
K Kali Zhou

Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots

This study evaluates barriers to early detection of liver cancer.

18 years of age All Phase N/A
A Ajay Goel, PhD

A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited. This study seeks to develop a cell-free tsRNA (cf-tsRNA)-based liquid biopsy assay for accurate detection of early-stage HCC.

18 years of age All Phase N/A

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

18 years of age All Phase 1/2
L Lianxin Liu, Doctor

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

This study is a randomized, controlled, open-label, multicenter, seamless Phase II/III trial designed to evaluate the efficacy and safety of the combination regimen of IBI310 and sintilimab in participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who are: (1) treatment-naive to systemic therapy; and (2) either unsuitable for curative-intent …

18 - 75 years of age All Phase 2/3
J Jamie McKenzie, MD

Sample Collection for Ongoing Research and Product Evaluation Study

The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple …

18 years of age All Phase N/A

Cancer Loyalty Card Study 2 (CLOCS-2)

Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along the diagnostic spectrum, from the first observation of …

18 years of age All Phase N/A
S Site Public Contact

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.

18 years of age All Phase N/A
M Marie LEQUOY, MD

Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma

The main objective is to describe the evolution of patients treated for a primary malignant hepatobiliary tumor (hepatocellular carcinoma or cholangiocarcinoma) over the long course.

18 years of age All Phase N/A
X Xuehao Wang

Immunotherapy for Hepatocellular Carcinoma

This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.

18 years of age All Phase N/A

Simplify language using AI